ChemoCentryx, Inc. (CCXI)
Stock Price:
$57.43 USD
2.45 (4.46%)
Updated Oct 23, 2020 12:42 PM EDT - Market open
Key Info
| Market Cap |
3.96B |
| Revenue (ttm) |
76.08M |
| Net Income (ttm) |
-29.81M |
| Shares Out |
68.89M |
| EPS (ttm) |
-0.50 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$57.43 |
| Previous Close |
$54.98 |
| Change ($) |
2.45 |
| Change (%) |
4.46% |
| Day's Open |
55.20 |
| Day's Range |
55.04 - 57.65 |
| Day's Volume |
309,542 |
| 52-Week Range |
7.50 - 65.43 |
More Stats
| Market Cap |
3.96B |
| Enterprise Value |
3.50B |
| Earnings Date (est) |
Nov 9, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
68.89M |
| Float |
52.53M |
| EPS (basic) |
-0.52 |
| EPS (diluted) |
-0.50 |
| FCF / Share |
-1.35 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5.48M |
| Short Ratio |
8.04 |
| Short % of Float |
10.42% |
| Beta |
1.68 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
52.01 |
| PB Ratio |
9.43 |
| Revenue |
76.08M |
| Operating Income |
-31.49M |
| Net Income |
-29.81M |
| Free Cash Flow |
-85.41M |
| Net Cash |
452.92M |
| Net Cash / Share |
6.57 |
| Gross Margin |
-44.89% |
| Operating Margin |
-41.39% |
| Profit Margin |
-39.20% |
| FCF Margin |
-112.27% |
| ROA |
-5.10% |
| ROE |
-12.10% |
| ROIC |
-19.00% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (8)
| Buy |
8 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$76.75*
(33.64% upside)
Low
63.0
Current: $57.43
High
100.0
Target: 76.75
*Average 12-month price target from 8 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 36.13 | 42.88 | 82.50 | 11.94 | - | - | 6.06 | 5.42 | 31.67 | 34.86 |
| Revenue Growth | -15.74% | -48.03% | 591.22% | - | - | - | 11.83% | -82.89% | -9.14% | - |
| Gross Profit | 36.13 | 42.88 | 82.50 | 11.94 | - | - | 6.06 | 5.42 | 31.67 | 34.86 |
| Operating Income | -58.30 | -40.27 | 16.49 | -40.72 | -47.69 | -47.40 | -39.12 | -39.63 | -4.30 | -5.96 |
| Net Income | -55.49 | -37.97 | 17.86 | -39.96 | -47.31 | -46.93 | -38.67 | -39.89 | -4.62 | -3.10 |
| Shares Outstanding | 56.90 | 49.81 | 48.41 | 46.43 | 43.89 | 43.28 | 40.92 | 35.41 | 4.21 | 4.08 |
| Earnings Per Share | -0.98 | -0.76 | 0.36 | -0.86 | -1.08 | -1.08 | -0.95 | -1.13 | -1.10 | -0.76 |
| Operating Cash Flow | -70.12 | 16.44 | 4.88 | 39.15 | -39.33 | -34.32 | -33.32 | -32.23 | 3.42 | 18.64 |
| Capital Expenditures | -0.79 | -0.84 | -0.72 | -0.30 | -0.22 | -0.35 | -0.55 | -0.47 | -0.17 | -1.19 |
| Free Cash Flow | -70.91 | 15.60 | 4.16 | 38.84 | -39.55 | -34.67 | -33.87 | -32.70 | 3.25 | 17.44 |
| Cash & Equivalents | 173 | 177 | 127 | 118 | 71.28 | 73.36 | 133 | 103 | 89.49 | 81.58 |
| Total Debt | 20.35 | 19.69 | 4.68 | - | - | - | 0.33 | 0.90 | 11.92 | 1.28 |
| Net Cash / Debt | 152 | 157 | 123 | 118 | 71.28 | 73.36 | 133 | 102 | 77.57 | 80.29 |
| Assets | 209 | 183 | 189 | 156 | 78.16 | 117 | 152 | 122 | 102 | 98.13 |
| Liabilities | 143 | 169 | 110 | 106 | 5.65 | 8.38 | 7.11 | 11.98 | 25.55 | 21.36 |
| Book Value | 66.00 | 14.74 | 79.27 | 49.89 | 72.51 | 109 | 145 | 110 | 76.00 | 76.77 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ChemoCentryx, Inc. |
| Country |
United States |
| Employees |
82 |
| CEO |
Thomas J. Schall |
Stock Information
| Ticker Symbol |
CCXI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: CCXI |
| IPO Date |
February 8, 2012 |
Description
ChemoCentryx, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.